Increasing apoA-I production as a target for CHD risk reduction

Area of Science:

• Cardiovascular Science
• Biochemistry
• Nutritional Science

Background:

• Dyslipidemia contributes to coronary heart disease (CHD), with current treatments primarily focused on lowering LDL cholesterol (LDL-C).
• Elevated high-density lipoprotein cholesterol (HDL-C) is associated with protection against CHD development, as shown in epidemiological studies.

Purpose of the Study:

• To explore strategies for preventing or treating CHD by targeting HDL-C beyond LDL-C reduction.
• To review methods for increasing HDL-C, focusing on pre-beta HDL particles and apolipoprotein A-I (apoA-I) production.

Main Methods:

• Review of literature on HDL-C metabolism and its role in CHD.
• Analysis of various approaches to increase HDL-C, including apoA-I infusion, mimetics, and delipidation.
• Examination of molecular pathways of apoA-I synthesis and secretion.
• Overview of pharmacological and nutritional effects on apoA-I synthesis.

Main Results:

• Increasing pre-beta HDL particle concentrations is presented as a potentially more attractive strategy than solely increasing alpha-HDL particles for elevating HDL-C.
• Elevating de novo apoA-I production is identified as a potential target for functionally increasing pre-beta HDL particle concentrations.
• The review details molecular pathways of apoA-I synthesis and secretion.

Conclusions:

• Strategies targeting apoA-I production can increase pre-beta HDL concentrations and serum HDL-C.
• This approach offers a novel avenue for CHD risk reduction, complementing existing LDL-C lowering therapies.
• Understanding apoA-I synthesis can inform the development of dietary interventions to lower CHD risk.